Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer

Documenti analoghi

• Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
  di: Qichen Zhang, et al.
  Pubblicazione: (2025)
• Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy
  di: Akihiro Ohara, et al.
  Pubblicazione: (2025)
• Postoperative Adjuvant Chemoradiotherapy ±  PD ‐1 Inhibitor for Locally Advanced Head and Neck Squamous Cell Carcinoma
  di: Zhiqiang Wang, et al.
  Pubblicazione: (2026)
• Marked Response to Nivolumab by a Patient With SMARCA4‐Deficient Undifferentiated Urothelial Carcinoma Showing High PD‐L1 Expression: A Case Report
  di: Yohei Arihara, et al.
  Pubblicazione: (2024)
• Rapid Development of Breast Mass With Recurrent Episodes of Hypoglycemia Should Raise Suspicion of Breast Cancer With Insulinoma: A Case Report
  di: Tingting Liu, et al.
  Pubblicazione: (2025)